Allakos CEO and leadership

Robert Alexander has been involved in the formation and leadership of numerous biotechnology companies. Robert Alexander was CEO of ZS Pharma where he led the initial public offering and sale of ZS Pharma to AstraZeneca. Prior to ZS Pharma, Robert Alexander was a Director at Alta Partners, a venture capital firm, and was also Executive Chairman and interim CEO of SARcode Bioscience. During his time at Alta Partners, he led investments in SARcode Bioscience (acquired by Shire), Lumena Pharmaceuticals (acquired by Shire), ZS Pharma (acquired by AstraZeneca), and Allakos. Prior to Alta Partners, Robert was a Principal in MPM Capital’s BioEquities Fund. Robert Alexander joined MPM from Genentech, where he worked in the Business Development group. Robert Alexander is on the Board of Directors of Allena Pharmaceuticals. He holds a PhD from the University of North Carolina at Chapel Hill and a Bachelor Science in Zoology from Miami University of Ohio.

Dr. Paterson has more than 25 years of pharmaceutical, biotech experience, and clinical practice. Dr. Paterson has led numerous Clinical Development and Medical Affairs teams resulting in multiple NDAs, supplemental new drug applications (sNDAs), and biologic license applications (BLAs) in gastrointestinal diseases and other indications. Prior to joining Allakos, Dr. Paterson was the Lead Physician for Immunodermatology at UCB Pharma. He was also a co-founder and CMO of Vivelix Pharmaceuticals, Senior Vice President of Medical and Clinical Development at Salix Pharmaceuticals, and additionally, has held various positions of increasing responsibility at GlaxoSmithKline, King Pharmaceuticals and Endo International.

Dr. Paterson previously served as Chief, Colon and Rectal Surgery, Associate Professor of Surgery at University of Massachusetts Medical School and Assistant Professor of Surgery at McMaster University Medical Center. Dr. Paterson holds an MD and an MSc (physiology and pharmacology) from McMaster University, Ontario, Canada and an MBA from the University of Tennessee.

Mr. Radford has over 25 years of public company finance and leadership experience at companies in multiple industries and various stages of growth including providing financial operations leadership to commercial-stage companies. Prior to Allakos, as Senior Vice President of Finance at Aimmune Therapeutics, Mr. Radford was responsible for all aspects of strategic and operational finance activities supporting the launch of its first approved product, including financial planning, controllership, tax and treasury functions. Prior to working at Aimmune Therapeutics, he served as the Chief Financial Officer at HeartFlow, a medical technology company with commercial operations in the United States, Canada, Europe and Japan. Prior to joining HeartFlow, Mr. Radford served as Vice President of Finance at Intuitive Surgical, with responsibility for financial planning and analysis, investor relations and enterprise analytics. Prior to Intuitive Surgical, Mr. Radford held various positions at eBay, including Vice President of Finance for Marketplaces Europe, as well as Vice President, Corporate Controller, and Chief Accounting Officer. Mr. Radford began his career in the audit practice of PricewaterhouseCoopers.

Mr. Radford has a BBA from Ohio University.

Dr. Paterson has more than 25 years of pharmaceutical, biotech experience, and clinical practice. Dr. Paterson has led numerous Clinical Development and Medical Affairs teams resulting in multiple NDAs, supplemental new drug applications (sNDAs), and biologic license applications (BLAs) in gastrointestinal diseases and other indications. Prior to joining Allakos, Dr. Paterson was the Lead Physician for Immunodermatology at UCB Pharma. He was also a co-founder and CMO of Vivelix Pharmaceuticals, Senior Vice President of Medical and Clinical Development at Salix Pharmaceuticals, and additionally, has held various positions of increasing responsibility at GlaxoSmithKline, King Pharmaceuticals and Endo International.

Dr. Paterson previously served as Chief, Colon and Rectal Surgery, Associate Professor of Surgery at University of Massachusetts Medical School and Assistant Professor of Surgery at McMaster University Medical Center. Dr. Paterson holds an MD and an MSc (physiology and pharmacology) from McMaster University, Ontario, Canada and an MBA from the University of Tennessee.

Robert Alexander has been involved in the formation and leadership of numerous biotechnology companies. Robert Alexander was CEO of ZS Pharma where he led the initial public offering and sale of ZS Pharma to AstraZeneca. Prior to ZS Pharma, Robert Alexander was a Director at Alta Partners, a venture capital firm, and was also Executive Chairman and interim CEO of SARcode Bioscience. During his time at Alta Partners, he led investments in SARcode Bioscience (acquired by Shire), Lumena Pharmaceuticals (acquired by Shire), ZS Pharma (acquired by AstraZeneca), and Allakos. Prior to Alta Partners, Robert was a Principal in MPM Capital’s BioEquities Fund. Robert Alexander joined MPM from Genentech, where he worked in the Business Development group. Robert Alexander is on the Board of Directors of Allena Pharmaceuticals. He holds a PhD from the University of North Carolina at Chapel Hill and a Bachelor Science in Zoology from Miami University of Ohio.